Clinical Trials

Phase 2 Active not recruiting

117 enrolled

Dermatologic

Melanoma

NCT03568058 2026-03-24

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

Phase 1 Completed

25 enrolled 12 charts

Tumor-Agnostic

Neoplasms

NCT04943848 2026-03-17

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Phase 1 Recruiting

36 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

120 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Phase 1 Recruiting

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

CNSEndocrineGenitourinary

40 enrolled

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT03983057 2026-02-11

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Phase 2 Completed

392 enrolled

Pancreatic Neoplasms

NCT04080804 2026-02-09

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07392320 2026-02-06

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

142 enrolled

Nasopharangeal Cancer

NCT05223231 2026-02-02

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Phase 1/2 Completed

26 enrolled

Advanced Malignant Tumors

NCT07381309 2026-02-02

VVSHIP

114 enrolled

Phase 1/2 Not yet recruiting

CRC

NCT07365592 2026-01-26

Neo-CD

138 enrolled

Colorectal Neoplasms

NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

250 enrolled

Neoplasms, Recurrence

NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

BreastDermatologicHead & NeckThoracic

98 enrolled

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

NCT06468280 2026-01-21

ROSETTE

84 enrolled

Stomach Neoplasms

NCT06475300 2026-01-21

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

570 enrolled

Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

40 enrolled

Phase 1/2 Active not recruiting

Advanced Malignant Solid Neoplasm

NCT05210413 2026-01-15

SPARTO

80 enrolled

Refractory or Recurrent Solid Tumor

NCT06265727 2026-01-08

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

348 enrolled

Phase 2 Active not recruiting

Solid Tumor, Adult

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT07318636 2026-01-06

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Phase 1 Not yet recruiting

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04146298 2025-12-24

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT04294160 2025-12-24

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

122 enrolled

Phase 3 Not yet recruiting

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

382 enrolled

Locally Advanced Low Rectal Adenocarcinoma

NCT06493240 2025-11-25

NLCCRIT-LARC

Phase 2 Completed

30 enrolled

Locally Advanced Rectal Cancer

NCT05631899 2025-11-24

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Phase 1/2 Not yet recruiting

9 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07245901 2025-11-24

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

60 enrolled

Solid Tumor

NCT02936102 2025-11-14

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

154 enrolled

BreastSarcoma

Chordoma, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT04058756 2025-10-07

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

120 enrolled

Phase 2 Active not recruiting

Advanced Solid Tumors

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

19 enrolled

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

GastrointestinalHead & NeckSarcomaThoracic

122 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT06008054 2025-09-26

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

376 enrolled

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05941507 2025-09-24

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

BreastCNSGastrointestinalGynecologicHead & NeckThoracic

300 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT03961971 2025-09-10

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Phase 2 Not yet recruiting

16 enrolled

CNS

Glioblastoma

NCT06512207 2025-09-09

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Phase NA Recruiting

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT06255223 2025-09-03

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

35 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05576480 2025-08-28

SPARC

55 enrolled

Rectal Neoplasms

NCT04191421 2025-08-22

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

35 enrolled 10 charts